Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

OSTEONECROSIS: A SUBSTANCE PROBLEM RATHER THAN A SURFACE DISEASE: IS RESURFACING A VIABLE SOLUTION?



Abstract

Introduction: In contrast to degenerative (OA) and inflammatory arthritides which are primarily joint surface diseases, femoral head osteonecrosis (ON) is a bone substance disease which extends to the surface. Is HR effective in ON?

Methods: This is a single-surgeon retrospective consecutive case-series with a 5 to 15-year (mean 9.5) follow-up of 95 patients (104 hips) with Ficat-Arlet III/IV ON treated with HR. Mean age is 43 (18 – 68) years. Two patients died from unrelated causes and none is lost to follow-up. Revision of either component for any reason was the end-point. Patients were assessed clinically and with hip function scores and anteroposterior, cross-table lateral radiographs.

Results: Ten failures (1 fracture, 6 femoral head collapse, 2 infections, 1 cup loosening) give a failure rate of 9.6% and 89% survivorship. All the above have been converted to total hip arthroplasty (THA). In one further patient the femoral component has tilted into varus. No other patient shows clinical or radiological adverse signs.

Discussion and Conclusion: Several studies in THA suggest that the results are generally worse in patients with ON compared to those with OA. Others find no difference. Our results show that the cumulative survival of HR in osteonecrosis is worse than that with other diagnoses. Further collapse of the femoral head is the most common reason for failure and it occurred between 3 and 9 years after implantation. HR was originally an option for hip joint surface disease such as OA. ON being a substance problem is in our hands a relative contraindication to hip resurfacing.

Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Tel: +41 44 448 44 00; Email: office@efort.org

Author: Joseph Daniel, United Kingdom

E-mail: mr.jdaniel@yahoo.co.uk